Regeneration Biomedical's Autologous Stem Cell Therapy for Alzheimer's Disease Advances to Phase 2 Following Positive Safety Data
核心洞察
Regeneration Biomedical (搜索)'s RB-ADSC autologous stem cell therapy demonstrated safety and tolerability in a phase 1 trial of 7 Alzheimer's disease (搜索) patients, with no adverse events reported following direct brain injection.
The therapy showed promising biomarker improvements, with 83% of patients experiencing reduced phosphorylated tau (搜索) levels and 66% showing improved amyloid (搜索) PET scores at 12 weeks.
The FDA has cleared a phase 2 randomized trial enrolling approximately 115 patients with mild-to-moderate Alzheimer's disease (搜索) to further evaluate the therapy's efficacy and optimal dosing.
Regeneration Biomedical (搜索) has advanced its autologous stem cell therapy for Alzheimer's disease (搜索) into phase 2 clinical testing following encouraging safety and preliminary efficacy data from a first-in-human study. The company presented results from its phase 1 trial at the 18th Clinical Trials on Alzheimer's Disease (CTAD) conference in San Diego, demonstrating that direct-to-brain delivery of Wnt (搜索)-enriched stem cells was well tolerated and showed promising biomarker improvements.
Phase 1 Trial Design and Patient Population
The dose-escalation study included 7 patients under 80 years of age with Mini-Mental State Examination (MMSE) scores between 11 and 20, representing mild to moderate Alzheimer's disease (搜索). All participants demonstrated elevated PET and cerebrospinal fluid (CSF) biomarkers indicative of Alzheimer's disease and were classified as FAST stage 4 or 5.
The treatment protocol involved harvesting 50 cc of lipoaspirate through liposuction, which was then purified, culture-expanded, and screened to ensure more than 50% of cells expressed Wnt (搜索) before cryopreservation. Patients underwent surgical placement of a subgaleal Ommaya reservoir with a catheter positioned in the right frontal horn of the lateral ventricle.
Treatment Administration and Safety Profile
Patients received intraventricular injections of 3 mL containing escalating cell doses: 2 million cells in cohort 1, 5 million in cohort 2, and 10 million in cohort 3. The cell product was administered an average of 48.5 days after the initial lipoaspirate procedure, with patients observed overnight following injection.
The therapy demonstrated a favorable safety profile across all dose levels. Minor adverse events were limited to the preparatory procedures, including minor bruising and discomfort following liposuction and mild incisional pain after Ommaya reservoir implantation. Notably, the 8-minute injection procedure required no anesthetic and produced no adverse events in any of the 7 participants through at least 25 weeks post-procedure.
Biomarker and Cognitive Outcomes
The study revealed encouraging preliminary efficacy signals across multiple measures. Eighty-three percent of treated patients demonstrated reductions in CSF phosphorylated tau (搜索) levels, with median values decreasing from 61.88 pg/mL (range 46.9-152.75) at baseline to 29.75 pg/mL (range 13.20-66.55) at 12 weeks post-injection.
Amyloid (搜索) burden also showed improvement, with 66% of patients experiencing better amyloid PET centiloid scores. The median score shifted from 137.2 (range 53.5-155.5) at baseline to 100.53 (range 55.6-168.1) at 12 weeks.
Cognitive assessments using the Alzheimer's Disease (搜索) Assessment Scale-cognitive subscale (ADAS-Cog) showed improvement in 83% of patients. Median scores decreased from 53 (range 40-69) before injection to 38 (range 20-69) at week 12, indicating better cognitive performance.
Phase 2 Trial Design
Based on these positive results, the FDA has cleared a phase 2 randomized, double-blind, placebo-controlled trial (NCT07205601) that began enrollment in November 2025. The study will enroll approximately 115 adults with mild-to-moderate Alzheimer's disease (搜索) using a 4:1 randomization to active treatment versus placebo.
Patients assigned to active therapy will be further stratified into two dose cohorts: a low dose of 2.5 × 10⁶ cells and a high dose of 5.0 × 10⁶ cells, resulting in a 2:2:1 overall randomization scheme. The therapy will be administered intracerebroventricularly every 2 months through the implanted Ommaya reservoir over 10 months, for up to 6 total injections, followed by 6 months of post-treatment monitoring.
Mechanism and Clinical Significance
"Our therapy uses autologous stem cells enriched for Wnt (搜索) expression, with the goal of stimulating dormant ventricular stem cell populations," explained Christopher Duma, MD, FACS, founder of Regeneration Biomedical (搜索) and inventor of the direct-to-brain delivery method. "The feasibility, safety, and early cognitive signals observed in this first-in-human study underscore the urgent need for regenerative strategies."
The phase 2 study's primary and secondary objectives will focus on cognitive and functional outcomes alongside CSF biomarker changes, including phospho-tau, total tau, and Aβ42. Additional assessments will include volumetric MRI using NeuroQuant and comparative diagnostic imaging such as amyloid (搜索) PET.
"With this FDA clearance, RBI advances into Phase 2 and continues its mission to develop a regenerative therapeutic that may restore, not just preserve, neural function," stated Bill Miller, chief executive officer at Regeneration Biomedical (搜索). The company is actively seeking strategic investment to support the continued development of this potentially transformative approach to Alzheimer's disease (搜索) treatment.